人参皂苷Rg1对大鼠脑缺血再灌注损伤细胞凋亡的影响

目的:研究人参皂苷Rg1对大鼠脑缺血再灌注损伤时细胞凋亡的影响。方法:采用大鼠右侧大脑中动脉阻断(middle cerebral artery occulusion,MCAO)局灶性脑缺血再灌注模型,缺血前给予人参皂苷Rg1 25、501、00 mg.kg-1灌胃,7 d。末次给药1h后制备MCAO模型,缺血2 h,再灌注22 h后,分别用Longa’s法T、TC染色法评价大鼠的神经功能状态及脑梗死面积;用TUNEL法测定缺血再灌后神经细胞凋亡的程度;用Western blot法测定大脑缺血侧脑组织中与凋亡相关基因Caspase-3、Bcl-2的蛋白表达。结果:人参皂苷Rg1(50、100 mg.kg-1)可明显减少MCAO再灌注后脑梗死面积,改善神经功能症状,与模型组比较具有显着性差异(P<0.05或P<0.01);脑缺血2 h再灌22 h后,模型组大鼠缺血侧细胞凋亡程度、Caspase-3蛋白表达明显增加,同时Bcl-2的蛋白表达降低。给予人参皂苷Rg1(50,100mg.kg-1)后,缺血侧细胞凋亡程度、Caspase-3蛋白表达降低,而Bcl-2的蛋白表达增加,与模型组相比具有统计学意义(P<0.01或P<0.05)。结论:人参皂苷Rg1对大鼠脑缺血再灌注损伤引起的细胞凋亡具有明显的保护作用,其机理可能与人参皂苷Rg1影响Caspase-3、Bcl-2的表达有关。     

黄芩苷对脑缺血-再灌注损伤大鼠神经细胞凋亡及相关基因表达的影响

目的:研究黄芩苷对大鼠局灶性脑缺血-再灌注损伤后神经细胞凋亡以及半胱氨酸天冬氨酸蛋白酶(caspase)-3、热休克蛋白(HSP)70表达的影响。方法:96只Wistar大鼠随机分为假手术组、脑缺血再灌注模型组、黄芩苷组(50,100,200 mg·kg-1),以及尼莫地平(0．4 mg·kg-1)组。利用大鼠大脑中动脉内栓线阻断法制备局灶性脑缺血-再灌注损伤模型,通过HE染色、流式细胞术、免疫组化以及RT- PCR等方法,观察黄芩苷对大鼠局灶性脑缺血-再灌注损伤后脑组织病理形态学改变、神经细胞凋亡率以及caspase-3、HSP70表达的影响。结果:黄芩苷可明显改善脑缺血-再灌注损伤所致的大鼠脑组织病理形态学改变,降低神经细胞凋亡率,抑制促凋亡基因caspase-3的表达,促进抑凋亡基因HSP70的表达。结论:黄芩苷对大鼠局灶性脑缺血-再灌注损伤具有保护作用,其作用机制可能与黄芩苷抑制caspase-3表达,促进HSP70表达,从而发挥抗凋亡作用有关。     

水飞蓟宾对局灶性脑缺血再灌注损伤大鼠保护作用的研究

目的 研究水飞蓟宾(SIL)对局灶性脑缺血再灌注损伤大鼠的保护作用,并探讨其可能的作用机制。方法 取112只清洁级雄性大鼠随机分为6组:假手术组、模型对照组、水飞蓟宾(100、200和400 mg·kg-1)预处理组和尼莫地平(32 mg·kg-1)预处理组,通过中动脉线栓法制备局灶性脑缺血再灌注大鼠模型。再灌注6 h后,进行神经功能评分,分析测定脑组织梗死体积及含水量;通过苏木精-尹红(HE)染色法观察脑组织形态学变化;测定血清中磷酸肌酸激酶(CPK)、乳酸脱氢酶(LDH)含量及总抗氧化能力(T-AOC)水平;测定脑组织中超氧化物歧化酶(SOD)、过氧化氢酶(CAT)活性和丙二醛(MDA)含量;通过TUNEL染色观察神经细胞凋亡状况并计算凋亡指数(AI),通过Western blot方法测定脑组织中NF-κB蛋白表达并进行半定量分析。结果 与模型组相比,水飞蓟宾(200和400 mg·kg-1)预处理组大鼠神经功能评分显著降低、脑梗死体积和含水量均显著降低,脑组织病理形态学变化及神经细胞凋亡均明显减轻,凋亡指数显著降低;脑组织中SOD、CAT活性显著升高且MDA含量显著降低;血清中CPK,LDH含量显著降低;脑组织中NF-κB蛋白表达量显著降低;水分蓟宾400 mg·kg-1预处理组血清中T-AOC水平显著升高;差异均具有统计学意义(P<0.05,P<0.01)。结论 水分蓟宾对局灶性脑缺血再灌注损伤大鼠具有保护作用,其作用机制可能与水分蓟宾能够改善局灶性脑缺血再灌注损伤大鼠脑组织中抗氧化酶活性、抑制氧化应激损伤有关。     

大鼠局灶性脑缺血/再灌注后NF-kB表达和细胞凋亡

目的:研究脑缺血再灌注后大鼠脑组织半暗区核因子(nuclear factor kappa B,NF-kB)基因表达的变化与神经细胞凋亡的关系。方法:用插线法制作大鼠大脑中动脉(M CAO)栓塞/再灌注模型,原位杂交法检测大鼠脑重度缺血(3h)及再灌注损伤不同时间点(2、3d)半暗区NF-kB表达;TUNEL法测定凋亡细胞。结果:脑缺血再灌注后,缺血半暗区NF-kB的表达明显升高(P<0.01)。凋亡细胞数量亦显著增加(P<0.01)。细胞凋亡的时程变化与NF-kB的表达基本一致。结论:局灶性重度脑缺血再灌注后可引起NF-K b表达的增加,参与缺血再灌注神经细胞损伤机制。     

法舒地尔可能通过PI3-K/Akt信号通路抑制大鼠脑缺血/再灌注区神经元的凋亡

目的探讨法舒地尔对大鼠脑缺血/再灌注损伤神经元是否具有抗凋亡作用并探讨其抗凋亡机制。方法大脑中动脉线栓法制作大鼠局灶性脑缺血/再灌注损伤模型。运用TUNEL法检测大鼠脑缺血/再灌注区神经细胞的凋亡,免疫组化法检测Bcl-2、Bax、Caspase-3蛋白的表达,Western blot法检测Akt以及Rho激酶特异性底物蛋白MYPT的磷酸化表达。结果法舒地尔能明显减少TUNEL染色阳性细胞数,增加Bcl-2的表达,降低Bax、Caspase-3的表达,升高Akt的磷酸化水平以及降低MYPT的磷酸化水平。结论①法舒地尔能减少大鼠脑缺血/再灌注区神经细胞凋亡。②法舒地尔的抗凋亡机制可能与其抑制Rho激酶活性,进而激活PI3-K/Akt传导通路有关。     

替勃龙对大鼠神经细胞Bcl-2、Bax表达的影响

目的探讨雌激素对去势大鼠脑缺血再灌注后神经细胞Bcl-2、Bax表达的影响和替勃龙的神经保护作用。方法 30只雌性成年SD大鼠,随机分为假手术组,手术对照组,替勃龙组,每组10只;采用大鼠大脑中动脉闭塞制成局灶性脑缺血模型。在缺血2h、再灌注24h后立即断头取脑,应用TTC染色观察脑梗死体积,TUNEL法检测凋亡细胞,链酶菌抗生物素蛋白过氧化物酶(SP)法检测抗凋亡基因Bcl-2、细胞凋亡诱导因子Bax的表达。结果替勃龙用药组较手术对照组脑梗死体积显著缩小(P<0.05),TUNEL阳性细胞数少(P<0.01),Bcl-2阳性细胞增多(P<0.01),Bax阳性细胞减少(P<0.01)。结论替勃龙可抑制去卵巢大鼠局灶性脑缺血再灌注时神经细胞凋亡,具有神经保护作用。     

缺血预处理对大鼠局灶性脑缺血再灌注损伤的影响

目的:探讨缺血预处理对大鼠局灶性脑缺血再灌注损伤的的保护作用。方法:SD大鼠60只,随机分为假手术组、模型组、预处理组。建立大鼠局灶性(MCAO)脑缺血再灌注损伤模型,预处理组24h前先行20min的缺血预处理,再缺血2h再灌注24h;假手术组不阻断血流,模型组未做缺血预处理。比较各组的神经功能评分、脑匀浆LDH、CK及MAD含量。结果:模型组神经功能障碍高于预处理组(P<0.01),模型组和预处理组大鼠脑缺血再灌注后脑匀浆LDH、CK明显低于假手术组(P<0.01),脑匀浆MAD明显高于假手术组(P<0.01),模型组大鼠脑缺血再灌注后脑匀浆LDH、CK明显低于预处理组(P<0.05),模型组大鼠脑缺血再灌注后脑匀浆MAD明显高于预处理组(P<0.05)。结论:缺血预处理对模型局灶性脑缺血再灌注损伤具有保护作用。     

氧化苦参碱对大鼠局灶性脑缺血损伤的保护作用及其抑制凋亡的作用机制

目的探讨氧化苦参碱(oxymatrine,OMT)对大鼠局灶性脑缺血损伤的保护作用及其抑制凋亡的作用机制。方法采用大鼠永久性大脑中动脉阻塞(permanent middle cer-ebral artery occlusion,pMCAO)方法,建立脑缺血模型,大鼠pMCAO术后通过腹腔给予OMT(30、60、120 mg.kg-1),以脑梗死体积、脑含水量和行为学症状等指标评价OMT对脑缺血的神经保护作用。通过HE染色方法观察OMT对缺血皮层神经细胞的形态变化以及数目的影响;应用Westernblot法检测OMT对缺血皮层Caspase-3、Bcl-2、Bax蛋白水平的表达。结果在大鼠局灶性脑缺血体内模型中,OMT(30、60、120 mg.kg-1)可明显减小脑梗死体积、脑含水量和改善行为学体征(P<0.01)。HE染色结果提示:OMT可明显增加神经细胞的存活率改善神经细胞的形态。Western blot结果显示:与假手术组相比,大鼠pMCAO后3、6、12、24 h,缺血皮层Caspase-3、Bax蛋白的表达水平在3 h开始上升,24 h达到峰值;而Bcl-2的表达水平在3h开始下降,24 h降到最低。给予OMT后可下调pMCAO大鼠缺血皮层中Caspase-3、Bax蛋白,上调Bcl-2蛋白。结论氧化苦参碱对脑缺血损伤有直接的神经保护作用,其机制可能通过上调Bcl-2及下调Bax、Caspase-3蛋白水平抑制凋亡发生。     

异丙酚对大鼠局灶性脑缺血和蛋白激酶C γ亚单位的作用

目的观察异丙酚对大鼠局灶性脑缺血和脑内蛋白激酶Cγ亚单位(PKCγ)变化的作用。方法♂SD大鼠随机分为Ⅰ:假手术组,Ⅱ:损伤组,Ⅲ:异丙酚(25mg·kg-1)+损伤组,Ⅳ:异丙酚(50mg·kg-1)+损伤组,Ⅴ:脂肪乳剂+损伤组,每组8例。采用大脑中动脉线栓法缺血3h再灌注24h。异丙酚和脂肪乳剂于再灌注前30min腹腔注射。通过原位末端脱氧核苷酸转移酶标记法观察局灶性脑缺血产生的神经细胞凋亡和异丙酚作用效果,免疫细胞化学法观察各组PKCγ蛋白在脑内表达变化的差异。结果再灌注24h后Ⅱ、Ⅲ、Ⅳ、Ⅴ组大鼠体重较缺血前降低(P<0.01),和Ⅰ组比较:Ⅱ、Ⅲ、Ⅳ、Ⅴ组大鼠再灌注24h后出现明显的神经体征缺陷(P<0.01),Ⅱ组大鼠额叶皮层和纹状体区域大量神经细胞凋亡,纹状体PKCγ蛋白表达明显下降。Ⅱ、Ⅲ、Ⅳ、Ⅴ组大鼠纹状体区域凋亡细胞密度与PKCγ染色阳性面积均没有差异(P>0.05)。结论再灌注前30min腹腔注射异丙酚对大鼠局灶性脑缺血再灌注损伤所致的神经细胞凋亡和PKCγ表达降低无保护作用。     

法舒地尔可能通过P13-K／Akt信号通路抑制大鼠脑缺血／再灌注区神经元的凋亡

目的探讨法舒地尔对大鼠脑缺血／再灌注损伤神经元是否具有抗凋亡作用并探讨其抗凋亡机制。方法大脑中动脉线栓法制作大鼠局灶性脑缺血／再灌注损伤模型。运用TUNEL法检测大鼠脑缺血／再灌注区神经细胞的凋亡，免疫组化法检测Bcl-2、Bax、Caspase-3蛋白的表达，Western blot法检测Akt以及Rho激酶特异性底物蛋白MYPT的磷酸化表达。结果法舒地尔能明显减少TUNEL染色阳性细胞数，增加Bcl-2的表达，降低Bax、Caspase-3的表达，升高Akt的磷酸化水平以及降低MYPT的磷酸化水平。结论①法舒地尔能减少大鼠脑缺血／再灌注区神经细胞凋亡。②法舒地尔的抗凋亡机制可能与其抑制Rho激酶活性，进而激活P13-K／Akt传导通路有关。     

In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke

The neuroprotective activity of ACEA 1021 (5-nitro-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione; licostinel), a selective antagonist at the strychnine-insensitive glycine site associated with the NMDA receptor complex, has been investigated in various models of focal cerebral ischemia. In isoflurane-anaesthesised Wistar rats with permanent ipsilateral carotid artery ligation and transient middle cerebral artery occlusion (duration of occlusion, 2 h) followed by reperfusion (24 h), intravenous administration of ACEA 1021 (bolus: 10 mg/kg, 15 min after the onset of middle cerebral artery occlusion; infusion: 7 mg/kg/h for 6 h beginning 30 min after occlusion of the artery) produced a 32% reduction in infarct volume. Similarly, in Sprague-Dawley rats with transient middle cerebral artery occlusion (2 h) followed by 24 h of reperfusion, identical treatment with ACEA 1021 decreased infarct size by 39%. Magnetic resonance imaging (MRI) confirmed these effects in the transient model, in that infarct volume observed using apparent diffusion coefficient (ADC) maps was significantly smaller after 24 h in the ACEA 1021-treated rats compared with Tris-treated controls. Furthermore, the increase in perfusion signal intensity after reperfusion was more pronounced in the ACEA 1021-treated rats than in controls. In Fisher 344 rats with permanent occlusion of the middle cerebral artery, ACEA 1021 induced a dose-related decrease in infarct volume, which was associated with an improvement in neurological outcome as measured by the rope suspension procedure. Administration of the same dose regimen, as above, in Fisher rats with permanent middle cerebral artery occlusion reduced infarct volume by 68%. This dose was as effective when administration was delayed for 2 h. In mice with permanent middle cerebral artery occlusion, ACEA 1021 (5 mg/kg, i.v., 5 min after occlusion; 30 mg/kg, s.c., 1 and 4 h post-middle cerebral artery occlusion) decreased infarct size by 42%. The consistent anti-ischemic effects of ACEA 1021 make it a valuable compound for exploratory stroke research.     

MC-002对大鼠局灶性脑缺血/再灌注治疗时间窗的研究

目的:研究受试药3-甲氧基-4-O-(2’-亚甲基-3’5’6’-三甲基吡嗪基)肉桂酸(MC-002)对大鼠局灶性脑缺血/再灌注损伤(CIRI)的治疗时间窗。方法:线栓法制作大鼠大脑中动脉闭塞(MCAO)2 h/再灌注22 h,并于复灌后0、0.5、1、2、4 h时治疗给药。观察MC-002对CIRI大鼠脑功能、脑梗死体积、脑含水量、组织形态学的影响以及MC-002各剂量组对大鼠脑组织内生化指标的影响。结果:MC-002在复灌后0、0.5、1、2 h给药能够显著性改善MCAO后大鼠的脑神经功能(P<0.05,P<0.01),降低大鼠的脑梗死率和含水量(P<0.05、P<0.01);增加CIRI大鼠脑组织超氧化物歧化酶(SOD)活力(P<0.01),降低丙二醛(MDA)及乳酸(LD)含量(P<0.05,P<0.01)。脑组织病理切片结果显示,和模型组比较,治疗组神经细胞形态和数目均得到显著改善。结论:MC-002 2 h内治疗给药对大鼠局灶性脑缺血/再灌注损伤有很好的保护作用。     

Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies.

In recent experimental studies, we demonstrated a highly beneficial neuroprotective effect of moderate- to high-dose human albumin treatment of transient focal cerebral ischemia, but we did not define the effect of albumin therapy in permanent focal cerebral ischemia. In this study, anesthetized Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion by retrograde insertion of an intraluminal nylon suture coated with poly-L-lysine. Albumin was administered i.v. at 2 h after onset of middle cerebral artery occlusion, in doses of either 1.25 (n=8) or 2.5 g/kg (n=6). In a separate group of animals, albumin (2.5 g/kg) was given 1 h after middle cerebral artery occlusion (n=6). Vehicle-treated rats (n=6) received 0.9% saline in equivalent volumes. Neurological status was evaluated during and 24 h after middle cerebral artery occlusion. One day after middle cerebral artery occlusion, infarct volumes and brain edema were determined. In a separate group of animals, cortical perfusion was assessed by Laser-Doppler perfusion imaging. Albumin (1.25 g/kg; n=3) or vehicle (sodium chloride 0.9%; n=3) was administered at 2 h after onset of middle cerebral artery occlusion. Higher-dose albumin therapy (2.5 g/kg) significantly improved the neurological score compared to vehicle rats at 24 h, when administered at either 1 or 2 h after middle cerebral artery occlusion. Total infarct volume was reduced by albumin (2.5 g/kg given at 2 h) by 32% compared with vehicle-treated rats. Both albumin doses (1.25 and 2.5 g/kg) significantly reduced cortical and striatal infarct areas at several coronal levels when administered at 2 h after middle cerebral artery occlusion. Brain swelling was not affected by albumin treatment. Cortical perfusion declined during middle cerebral artery occlusion in both groups. Treatment with albumin led to 48% increases in cortical perfusion (P<0.002), but saline caused no change. These results support a beneficial effect of albumin therapy in permanent focal cerebral ischemia.     

Beta-hydroxybutyrate,a cerebral function improving agent,protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia

In our previous study, beta-hydroxybutyrate (BHB) was found to prolong survival time and to inhibit cerebral edema by improving energy metabolism in the hypoxia, anoxia and global cerebral ischemia models. In this study, the cerebroprotective effect of BHB was examined in rats with permanent (p)-occlusion and transient (t)-occlusion of middle cerebral artery (MCA). BHB (30 mg x kg(-1) x h(-1) was continuously administered through the femoral vein. In rats with p-MCA occlusion, BHB significantly reduced infarct area at 24 h after the occlusion, but not at 72 h after the occlusion. In rats with 2-h t-MCA occlusion followed by 22-h reperfusion, BHB significantly reduced cerebral infarct area, edema formation, lipid peroxidation and neurological deficits. Moreover, in the t-MCA occlusion model, delayed administration of BHB started at 1 h after the initiation of the MCA occlusion also significantly reduced cerebral infarct area. Taking together the results obtained in our previous study into account, these results indicate that BHB decreased cerebral edema formation and infarct area by improving of the cerebral energy metabolism during ischemia and by inhibition of lipid peroxidation after reperfusion.     

Increased brain damage after ischaemic stroke in mice lacking the chemokine receptor CCR5

Background and purpose:

The chemokine receptor CCR5 is well known for its function in immune cells; however, it is also expressed in the brain, where its specific role remains to be elucidated. Because genetic factors may influence the risk of developing cerebral ischaemia or affect its clinical outcome, we have analysed the role of CCR5 in experimental stroke.

Experimental approach:

Permanent cerebral ischaemia was performed by occlusion of the middle cerebral artery in wild-type and CCR5-deficient mice. Locomotor behaviour, infarct size and histochemical alterations were analysed at different time points after occlusion.

Key results:

The cerebral vasculature was comparable in wild-type and CCR5-deficient mice. However, the size of the infarct and the motor deficits after occlusion were markedly increased in CCR5-deficient mice as compared with wild type. No differences between wild-type and CCR5-deficient mice were elicited by occlusion with respect to the morphology and abundance of astrocytes and microglia. Seven days after occlusion the majority of CCR5-deficient mice displayed neutrophil invasion in the infarct region, which was not observed in wild type. As compared with wild type, the infarct regions of CCR5-deficient mice were characterized by increased neuronal death.

Conclusions and implications:

Lack of CCR5 increased the severity of brain injury following occlusion of the middle cerebral artery. This is of particular interest with respect to the relatively frequent occurrence of CCR5 deficiency in the human population (1–2% of the Caucasian population) and the advent of CCR5 inhibitors as novel drugs.     

川芎、当归萃取液对实验性急性脑梗死大鼠行为学和脑组织损伤的影响

目的：通过建立大鼠急性脑梗死模型。观察不同剂量的川芎，当归萑取液与阳性药物（尼莫地平）对大鼠急性脑梗死的行为和病理等影响。方法：各实验组大鼠在术后清醒（术后4h及28h)2次给药，并进行2次行为检查（术后4及52h)和第2次给药后24h(术后52h)进行大鼠脑组织病理切片检查。结果：给川芎，当归萃取液及阳性药物后的大鼠行为积分值明显低于对照组，且脑部病理损害程度明显轻于溶剂组，结论：川芎、当归萃取液对急性阻断大脑中动脉所致脑缺血造成大鼠行为障碍具有明显的缓解治疗作用。对大鼠中动脉阻断后脑缺血造成的脑部病理损害具有保护，减轻作用。     

白三烯受体拮抗剂ONO—1078对大鼠局灶性脑缺血的神经保护作用

AIM: To determine whether ONO-1078 (pranlukast), a potent leukotriene receptor antagonist, has neuroprotective effect on focal cerebral ischemia in the rat. METHODS: Focal cerebral ischemia was induced by 30 min of middle cerebral artery (MCA) occlusion and followed by 24 h reperfusion. ONO-1078 (0.003-1.0 mg/kg) or vehicle (saline 1 mL/kg) was ip injected 30 min before MCA occlusion and 2 h after reperfusion. The neurological score, infarct volume, neuron density (in cortex, hippocampus, and striatum), brain edema, and albumin exudation around the vessels were determined 24 h after reperfusion. RESULTS: ONO-1078 slightly improved the neurological deficiency, and dramatically decreased infarct volume and neuron loss which showed a bell shaped dose response effect with highest effect at doses of 0.01-0.3 mg/kg. Enlargement of the ischemic hemisphere and albumin exudation were inhibited at doses of 0.01-1.0 mg/kg. CONCLUSION: ONO-1078 has the protective effect on focal cerebral ischemia in rats, which is partially attributed to the inhibition of brain edema. This may represent a novel approach to the treatment of acute cerebral ischemia with cysteinyl leukotriene receptor antagonists.     

L-盐酸赖氨酸对局部脑缺血大鼠的治疗作用

研究L-盐酸赖氨酸对大鼠局限性脑缺血的治疗作用。方法：采用电凝阻断大鼠一侧大脑中动脉造成局限性脑缺血模型。结果：一侧大脑中动脉阻断后15minipL-盐酸赖氨酸621.5及310.8mg.kg^-1,能显著降低局限性脑缺血大鼠的脑梗塞面积,减少相关脑区变性、坏死神经元的数量,而且L-盐酸赖氨酸621.5mg.kg^-1还能明显改善大鼠的神经功能缺失,降低行为评分。 结论：L-盐酸赖氨酸对脑缺血有治疗作用。     

Effects of the Calcium Antagonist AE0047 on the Development of Neurological Deficit and Infarction after Middle Cerebral Artery Occlusion in Stroke-prone Spontaneously Hypertensive Rats

AE0047 [4-(4-benzhydrylpiperazino)phenethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine dicarboxylate dihydrochloride] is a new dihydropyridine calcium antagonist with protective effects against cerebral ischaemia and the occurrence of stroke in several animal models. We investigated the effects of AE0047 on focal ischaemia induced by middle cerebral artery occlusion in stroke-prone spontaneously hypertensive rats. AE0047 at a dose causing 20 or 40% systemic hypotension (1 or 3 mg kg^?) was given orally twice, 15 min and 24 h after occlusion. The neurological status of animals was investigated 2, 24 and 48 h after occlusion. Infarct area of brain was measured 48 h after occlusion. Middle cerebral artery occlusion resulted in the progressive deterioration of neurological status and large infarction in middle cerebral artery territories with 40% mortality. AE0047 dose-dependently attenuated the deterioration of neurological status, and reduced mortality to 0 or 10%. AE0047 significantly reduced infarct size and left/right hemispheric area ratio, an index of brain swelling. These results suggest that AE0047 has the ability to ameliorate ischaemic cerebral stroke in hypertensive patients.     

缺血再灌注时间对小鼠大脑中动脉闭塞模型的影响

目的:探讨不同缺血时间对小鼠大脑中动脉闭塞(MCAO)所致脑缺血-再灌注损伤的影响。方法:以雄性C57BL/6J小鼠为研究对象,线栓法致小鼠局灶性脑缺血,分别在缺血0.5,1和2 h后进行再灌注。再灌注24 h后,进行神经行为学评分,计算存活率、脑梗死率及脑水含量。结果:缺血后各组小鼠均出现不同程度的缺血损伤。缺血1 h再灌注24 h组小鼠出现明显的神经行为缺陷,脑梗死体积和脑水含量与假手术组相比有显著性差异,且变异系数最小,显示其最稳定。结论:缺血1 h再灌24 h可引起小鼠大脑中动脉供血区域梗死大小适宜,稳定性好,可作为研究脑缺血生理病理和药效学评价的动物模型。